Form 4: Aytu BioPharma CEO Joshua Disbrow Buys 15,000 Shares on the Open Market

Aytu BioPharma's CEO, Joshua R. Disbrow, recently purchased 15,000 shares of the company's common stock in open market transactions.

Summary

• On February 28, 2025, Joshua R. Disbrow, the CEO of Aytu BioPharma, Inc., acquired 15,000 shares of the company's common stock.
• The shares were purchased through multiple open market transactions.
• The prices paid per share ranged from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share.
• Following the reported transaction, Mr. Disbrow directly owns 86,591 shares of Aytu BioPharma's common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase suggests confidence, but it's a relatively small transaction and doesn't provide definitive insight into the company's overall health.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor among many to consider when evaluating a company's potential.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates